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Introduction
The second most common malignancy amongst males worldwide is prostate cancer, as of
20191. The prostate is a gland that sits inferior to the urinary bladder and anterior to the rectum.
The urethra runs through the superior to inferior portion from the bladder and the seminal
vesicles connect to the prostate posteriorly to the bladder. Roughly 95% of these cancers are
adenocarcinomas, but other types include adenoid cystic, basal cell, urothelial, small-cell
neuroendocrine, squamous cell, and sarcomatoid carcinomas 1. Risk factors for prostate cancer
are high prostate specific antigen (PSA) measurements, older age, male sex, ethnicity (higher
mortality in black men), family history, genetic mutations, obesity, and poor diet 1. Organs at risk
when treated with external beam radiation therapy (EBRT) are the bladder, rectum, spinal cord,
femoral heads, penile gland, small bowel, and colon. General side effects of prostate cancer
treatments are urinary symptoms (incontinence), bowel functions (urgency/frequency), and
sexual impotence1. Hydrogel spacers for EBRT between the rectum and prostate have become
common practice as this extra separation reduces rectal toxicities while allowing full coverage of
the prostate/seminal vesicles2.
Prostate cancer treatment options range from periodic observation to a combined
treatment approach. The different treatment modalities for prostate cancer include surgery,
radiation therapy, chemotherapy, and hormone therapy1. The most common conventional
prostate radiation treatment is treated to a total dose of 76-80 Gray (Gy) in daily 1.8-2Gy
fractions (approximately 8 weeks)3. Hypofractionation schedules are also seen which treat a total
dose of 70Gy in daily 3.5Gy fractions (approximately 4 weeks) 3. SBRT may also be used to
treat low-risk patients with fractionation dose ranges from 6-15Gy in 5 treatments over the
course of two weeks3.
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Stereotactic body radiation therapy (SBRT) as defined by the American Society for
Radiation Oncology (ASTRO) as “an external beam radiation therapy method used to very
precisely deliver a high dose of radiation to an extracranial target within the body, using either a
single dose or a small number of fractions4.” This treatment technique was developed in the early
1990’s in Stockholm, Sweden from using similar concepts as stereotactic radiosurgery (SRS) 4.
Cyberknife (CK) was invented by Dr. John Adler in the 1990’s in Stanford, USA 5. This
technology made SBRT treatments more achievable as this new linear accelerator attached to a
robotic arm offering six degrees of freedom, making noncoplanar treatment very easy 5. CK also
has tumor-tracking capabilities such as “6D skull, fiducial, X sight spine, X sight lung with
Synchrony, and fiducial with Synchrony5.” The perceived benefits of cyberknife include submillimeter accuracy, moving target tracking, continuous treatment with normal breathing cycles,
and infinite non-isocentric beam angles. The greatest limitation of this technology is that it is
only suitable for smaller lesions, as treatment times are prolonged when compared to
conventional SBRT.
An abstract published in 2019 demonstrated how SBRT can be used to treat low-risk
prostate adenocarcinoma with a variety of treatment modalities 6. Twenty-seven random patients
treated with 36.25Gy in 5 fraction over a week had plans created with the same dose objectives
to find any significant advantages. The planning methods included “intensity modulated arc
therapy (IMRT) techniques as Sliding Window (SW), volumetric modulated arc therapy
(VMAT), and helical tomotherapy (HT), as well as Cyber Knife (CK) system 6.” The results
revealed that the rectum and bladder were spared more at medium/high doses (18Gy-36.25Gy)
by IMRT techniques when compared to CK. There was however no clear best treatment
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technique as they all had very conformal dose distributions and achieved organs at risk (OAR)
constraints.
Another study completed in 2016 compared conventional linear accelerator (LINAC)
versus the robotic arm CK for SBRT prostate cancer3. The results revealed that genitourinary
(GU) toxicities, gastrointestinal (GI) toxicities, and biological failure (BF) rates were similar for
both techniques. This study had several shortcomings such as a small number of patients and
short follow-up time after treatment. Another disadvantage of this study was the test group,
which was composed of mainly low-stage prostate cancer patients. Shorter treatment times were
annotated in the gantry-based SBRT (about 15 minutes) when compared to CK SBRT (about 45
minutes) 3.
An important aspect of EBRT is the divide between primary and boost treatment
schemes. The conventional primary treatment for intact prostate is 45Gy and this encompasses
the prostate, seminal vesicles, and any nodal involvement. The boost dose narrows down to just
the prostate gland and goes to a total dose 76-78Gy 7. A retrospective study in 2016 looked at
nine different centers and assessed SBRT treatments for intermediate-risk prostate cancer
(IRPC)8. The study concluded that linear accelerator SBRT prostate boost treatments also
showed promising GI and GU toxicities with a “rapid biochemical response 8.” The only
restriction within this study was that all the treatments were LINAC-based, not showing the
added variation of techniques that CK brings to the equation.
A study done in 2010 compared single fraction SBRT for spinal metastasis using CK vs.
Linac-based intensity modulated radiation therapy (IMRT) which had some interesting results 8.
They concluded that SBRT done with Linac-based IMRT had “less high dose spillage than the
CK plans in most cases9.” The CK plans did have an optimal minimum dose to the target volume
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(Dmin), but cord constraints could not always be met. This study is one of the primary reasons
that further research is needed to differentiate the most effective treatment for every cancer.
The purpose of this study is to retrospectively evaluate the quantitative difference of
prostate SBRT boost between LINAC boost (LINAC-BOOST) and CK boost (CK-BOOST)
treatments, with a primary plan using LINAC volumetric modulated arc therapy (VMAT). The
investigator is making this comparison between the modalities to find out if LINAC-based SBRT
for prostate boost treatments can be considered the on par with their CK counterparts. The
parameters that will be measured in this study are planned tumor volume (PTV) coverage,
conformity index, gradient index, global hotspot, Dmin, organs-at-risk (OAR’s) dose, and
treatment time. There will be side-by-side comparison of the boost plans as well as plan
summary for the entirety of the treatments. The researcher hypothesizes that Cyberknife-based
SBRT for prostate boost will provide an optimal plan overall when compared to LINAC-based.
Null hypothesis (H0): Linac-based SBRT will not show any quantitative differences
versus Cyberknife SBRT for prostate boost.
Alternative hypothesis (Ha): Linac-based SBRT will show quantitative differences versus
Cyberknife SBRT for prostate boost.

Methods
Patient selection
This study is a retrospective quantitative analysis of nine male prostate adenocarcinoma
patients previously treated at a southwest institution. The subjects were male patients over the
age of 18 that were treated from September 2021 to January 2022. The patients included had a
LINAC primary plan and an SBRT CK (G3 robot) prostate boost. The age of the subjects ranged
from 58 years to 75 years, with an average age of 67.7 years. The staging of the patients ranged
5

from IIc (intermediate) to IIIc (very high-risk) prostate cancers. The Gleason Score range was
from 6 to 9, with an average of 7.3.
Ethical considerations
The study was verbally approved by the data privacy officer at the southwest institution
as patients were previously treated and the data would be anonymized. This study was also
approved by the Grand Valley State University (GVSU) Institutional Review Board (IRB) under
the exempt review category. This project was reviewed by a staff dosimetrist who created the
identifiable data linkage code that was subsequently accessed by the research team. The primary
investigator and members of the research team were not allowed information that would permit
the identification of research subjects. There was no intervention or interaction with identified
human subjects during the conduct of this research project. Complete confidentiality of research
subjects' information was kept maintained. After the sample population was selected, personal
identifiers were destroyed, and the data was anonymized using MIM (v7.1.4). The linkage code
was destroyed upon completion of the study.
Simulation
Each patient had four gold fiducials and a hydrogel spacer implanted one to two weeks
prior to the primary treatment simulation to allow for swelling to subside. The patients were
simulated using a Siemens SOMATOM Sensation Open CT machine supine, headfirst on a
pillow, ring on chest, with a vaclock under the legs. Additional scans collected for tumor
delineation were T1 MRI with/without contrast, T2 with/without contrast, and a 3D series. The
scans were then sent to MIM for delineation of tumor volumes before being exported to Pinnacle
(v4.6.1) treatment planning system (TPS).
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A second CT scan from mid-kidney down to the mid-thigh was taken within the last two
weeks of the primary treatment for the CK-BOOST. All patients were set up lying head-first,
supine on a pad for simulation. The scan was then reconstructed in MIM for the radiation
oncologist tumor delineation. Patients started boost treatment within two weeks of finishing their
primary treatment.
Planning: primary treatment
Planning of the primary treatment was completed by a staff dosimetrist at a southwest
institution, not the researcher. The primary treatment was completed on the Pinnacle TPS. The
PTV expansion included the prostate and seminal vesicles with up to a 0.8 cm margin, except
posteriorly towards the rectum which was a 0.5 cm expansion. The hotspot was kept under a
maximum of 110% of the prescription dose. The prescription dose ranged from 41.4 Gy in 23
fractions to 50.4 Gy in 28 fractions. Two to four full and/or partial VMAT arcs were used for
these plans with 6 MV photon energy. The machines that were used for treatment was a Varian
21IX, Elekta Synergy, and Elekta Infiniti.
For planning evaluation, the institution followed RTOG 0521 recommendations for
organs at risk (OAR), which include the rectum, bladder, femoral heads, and penile bulb 10. The
external genitalia are defined as the “scrotum, perineal body, corpus cavernosum penis, and
surrounding pre-pubic fat11.” Per the recommendations, 17% of the rectum can receive less than
36 Gy (ideally <28 Gy) and 40% can receive less than 21 Gy (ideally <16.8 Gy). The bladder
constraints were 25% can receive less than 36 Gy (ideally <40 Gy) and 50% can receive less
than 21 Gy (ideally <16.8 Gy). For the femoral heads, 10% can receive less than 36 Gy (ideally
<22.4 Gy), and for the penile bulb, 50% can receive less than 31 Gy (ideally <25 Gy).
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Planning: boost treatments
Planning of the retrospective LINAC-BOOST was completed by the researcher, while the
CK-BOOST treatment was completed by other staff dosimetrists prior to this study that were
used for treatment. The CK-BOOST was completed on the Multiplan (v14) TPS, while the
LINAC-BOOST was planned in the Pinnacle TPS.
The nine patients had been treated with a SBRT fractionated schedule of 21 Gy in 3
fractions, given every other day over the course of a week. The LINAC-BOOST created by the
researcher followed the same fractionation schedule, treatment volumes, OAR, and dose
constraints as the original CK-BOOST treatment. Organs contoured included the bladder,
rectum, penile bulb, left and right femoral heads, sigmoid colon (if in field), and bowel (if in
field), and external genitalia. The PTV for the boost included the prostate only with a margin of
5mm all around, except posteriorly where abutting the rectum which was 3mm.
The CK-BOOST plans were created in Multiplan utilizing inverse planning to provide
proper PTV coverage while sparing normal tissue. The variable-aperture iris with a range of five
to sixty millimeters and hundreds of non-isocentric beams was used for these plans. The CK arm
stays in place while the head of the machine delivers beams associated with the node group, then
the arm moves again. The range of nodes was 57 to 71 and the total number of beams used
ranged from 184 to 350. The CK-BOOST plans were planned within the range of about 125155% hotspot and goal of prescription coverage to at least 95% of the PTV. The imaging for
prostate patients was kept at 45 kV images per minute and could be adjusted up to 150 during
treatment if patient movement was an issue.
The LINAC-BOOST plans were created in Pinnacle utilizing inverse planning to achieve
ideal PTV coverage while sparing the OAR. The LINAC-BOOST was treated with 3-6 full
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and/or partial VMAT arcs and on the same machine that the primary treatment was completed
on. The hotspot of the LINAC-BOOST plan was kept to about a 143% hotspot, as that was the
approximated average hotspot of the CK-BOOST plans and goal of prescription coverage to at
least 95% of the PTV. The plans generated for all the LINACS use 6 MV photon energy.
Imaging for this type of treatment on a LINAC would consist of cone beam computed
tomography (CBCT) scans taken prior to each arc.
For planning evaluation, the observational study by Hirsch, A. 12 recommendations were
followed for the delineated OAR’s. Both the CK-BOOST and LINAC-BOOST were planned to
utilize the same organ constraints. Per the protocols, <10cc (<20cc for minor variance) of the
bladder can receive no more than 19.5 Gy (V19.5 [cc]), 10% of the bladder can receives less than
18.9 Gy (V18.9 (%)), and 50% of the bladder receives less than 10.5 Gy (V10.5 (V10.5 (%)). Per
the protocols, <1cc (2cc for minor variance) of the rectum can receive no more than 19.5 Gy
(V19.5 [cc]), 10% of the rectum receives less than 18.9 Gy (V18.9 (%)), 20% of the rectum
receives less than 16.8 Gy (V16.8 (%)), and 50% of the rectum receives less than 10.5 Gy (V10.5
(%)). Per the protocols, 50% of the penile bulb (75% for minor variation) receives less than 15
Gy (V50 (%)). Per the protocols, 5% of the femoral heads receive less than 8 Gy (V8 (%)). Per
the protocols, <1cc (2cc for minor variances) of the sigmoid colon and bowel can receive no
more than 15 Gy (V15 [cc]).
Data analysis
Data that was gathered from the dose volume histograms (DVH) and plan constraints
were transferred to an Excel spreadsheet. The data collected included: PTV coverage, PTV
Dmin, PTV Dmax, conformity index (CI), gradient index (GI), global hot spot, OAR Mean,
OAR Dmax, and constraint, and estimated treatment time (minutes). The conformity index is
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defined as the treated volume enclosed by the 100% isodose line divided by PTV volume. The
gradient index is defined as the treated volume enclosed by the 50% isodose line divided by the
PTV volume13. The estimated treatment time calculation for the LINAC-BOOST was calculated
on a 600 MU/Min in Pinnacle TPS using the following formula: total daily MU / 600 Mu/Min.
For data analysis, nonparametric tests were used to compare similarities and differences
in means between the CK-BOOST and LINAC-BOOST plans. Nonparametric test “do not rely
on assumptions about shape or form of the probability distribution from which the data were
drawn14.” Comparing two quantitative measurements (CK and LINAC plans) from the same
patient, the Wilcoxon signed-rank test was used, and no corrections were made for multiple
testing. The statistical software used for data analysis was SAS Institute Inc. SAS® OnDemand
for Academics: Studio.; 2022.

Results
PTV (intact prostate)
The PTV coverage for both boost plans were evaluated on a generated DVH and were
covered between 93.38% to 98.49% by the prescription dose, which can be seen in Table 1. The
PTV Dmin on CK-BOOST plans ranged from 78.31% to 93.56% of prescription dose, with a
median of 86.05% and mean of 86.34%. On LINAC-BOOST plans, the PTV Dmin ranged from
68.3% to 88.74% of prescription dose, with a median of 78.61% and mean of 78.76%. A
Wilcoxon signed-rank test indicated that the CK-BOOST PTV Dmin was significantly higher
than the LINAC-BOOST PTV Dmin, Z = -22.5, p = 0.004. The PTV Dmax on CK-BOOST
plans ranged from 135.14% to 158.75% of prescription dose, with a median of 149.14% and
mean of 146.97%. On LINAC-BOOST plans, the PTV Dmax ranged from 142.36% to 143.8%
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of prescription dose, with a median of 143% and mean of 143.08%. A Wilcoxon signed-rank test
indicated that there were no significant differences in PTV Dmax, Z = -10.5, p = 0.25.
The CI on CK-BOOST plans ranged from 0.99 to 1.39, with a median of 1.07 and mean
of 1.09. On the LINAC-BOOST plans, the CI ranged from 0.96 to 1.04, with a median of 0.99
and mean of 1. A Wilcoxon signed-rank test indicated that the CK-BOOST CI was significantly
higher than the LINAC-BOOST CI, Z = -22.5, p = 0.004. The GI on CK-BOOST plans ranged
from 3.24 to 4.59, with a median of 4.19 and mean of 4.1. On LINAC-BOOST plans, the GI
ranged from 3.75 to 4.43, with a median of 3.94 and mean of 3.97. A Wilcoxon signed-rank test
indicated that there were no significant differences in GI, Z = -5.5, p = 0.55.
Rectum
On CK-BOOST plans, the rectum Dmax dose ranged from 83.84% (1760.64 cGy) to
111.4% (2339.4 cGy) of prescription dose, with a median of 102.24% (2147.04 cGy) and mean
of 100.37% (2107.77 cGy). On LINAC-BOOST plans, the rectum Dmax ranged from 82.57%
(1733.97 cGy) to 125.45% (2634.45 cGy) of prescription dose, with a median of 106.1% (2228.1
cGy) and mean of 101.36% (2128.56 cGy). A Wilcoxon signed-rank test indicated that there
were no significant differences in rectum Dmax, Z = 0.5, p = 1.
The rectum mean dose was also evaluated on both plans. The CK-BOOST plans showed
a median rectum dose of 686 cGy, with a range of 535.96 cGy to 931.33 cGy, with a mean of
722.59 cGy. On LINAC-BOOST plans, the rectum mean dose ranged from 351.2 cGy to 880.6
cGy, with a median of 530.30 cGy and a mean of 574.08 cGy. After performing a Wilcoxon
signed-rank test, it is statistically significant that the CK-BOOST rectum mean is higher than the
LINAC-BOOST rectum mean, Z = -17.5, p = 0.039.
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The rectum V19.5 [cc], V18.9 (%), V16.8 (%), and V10.5 (%) were evaluated on a
generated DVH and box plot figures 1-4 show the distribution of both plans. After performing a
Wilcoxon signed-rank test, significant differences were seen in the rectum V19.5 (Z = -18, p =
0.008), V18.9 (Z = -18, p = 0.008), and V16.8 (Z = -22.5, p = 0.004). The CK-BOOST plans
were significantly higher than the LINAC-BOOST plans in the previously stated distributions.
There were no significant differences in the comparison of the rectum V10.5 between the two
boost plans.
Bladder
On CK-BOOST plans, the bladder Dmax dose ranged from 102.01% (2142.21 cGy) to
118.58% (2490.18 cGy) of prescription dose, with a median of 105.95% (2224.95 cGy) and
mean of 107.86% (2265.06 cGy). On LINAC-BOOST plans, the rectum Dmax ranged from
110.84% (2327.64 cGy) to 122% (2562 cGy) of prescription dose, with a median of 114.37%
(2401.77 cGy) and mean of 115.46% (2424.66 cGy). A Wilcoxon signed-rank test indicated that
the bladder Dmax is significantly higher for the LINAC-BOOST than the CK-BOOST, Z = 20.5,
p = 0.012.
The bladder mean dose was also evaluated on both plans. The CK-BOOST plans showed
a median bladder dose of 595.96 cGy, with a range of 271.6 cGy to 1126 cGy, with a mean of
644.15 cGy. On LINAC-BOOST plans, the bladder mean dose ranged from 133.7 cGy to 931
cGy, with a median of 318.2 cGy and a mean of 375.89 cGy. After performing a Wilcoxon
signed-rank test, it is statistically significant that the CK-BOOST bladder mean is higher than
LINAC-BOOST bladder mean, Z = -22.5, p = 0.004.
The bladder V19.5 [cc], V18.9 (%), and V10.5 (%) were evaluated on a generated DVH
and box plot figures 5-7 show the distribution of both plans. After performing a Wilcoxon
12

signed-rank test, significant differences were seen in the bladder V19.5 (Z = -22.5, p = 0.004)
and V18.9 (Z = -22.5, p = 0.004). The CK-BOOST plans were significantly higher than the
LINAC-BOOST plans in the previously stated distributions. There were no significant
differences in the comparison of the rectum V10.5 between the two boost plans.
Penile bulb
On CK-BOOST plans, the penile bulb Dmax dose ranged from 4.4% (92.4 cGy) to
62.48% (1312.08 cGy) of prescription dose, with a median of 14.95% (313.95 cGy) and mean of
23.31% (489.51 cGy). On LINAC-BOOST plans, the penile bulb Dmax ranged from 3.89%
(81.69 cGy) to 13.75% (288.75 cGy) of prescription dose, with a median of 7.55% (158.55 cGy)
and mean of 8.27% (173.67 cGy). A Wilcoxon signed-rank test indicated that the CK-BOOST
penile bulb Dmax is significantly higher than the LINAC-BOOST penile bulb Dmax, Z = -21.5,
p = .008.
The penile bulb mean dose was also evaluated on both plans. The CK-BOOST plans
showed a median penile bulb dose of 136 cGy, with a range of 56.74 cGy to 654.4 cGy, with a
mean of 209.58 cGy. On LINAC-BOOST plans, the penile bulb mean dose ranged from 48 cGy
to 131.1 cGy, with a median of 100.6 cGy and a mean of 105.13 cGy. After performing a
Wilcoxon signed-rank test, it is statistically significant that the CK-BOOST penile bulb mean is
higher than LINAC-BOOST penile bulb mean, Z = -18.5, p = 0.027. The penile bulb V15
constraint did not apply to any plans as they received less than 15 Gy.
Femoral heads
On the CK-BOOST plans, the left/right femoral head Dmax dose ranged from
17.78%/21.96% (373.38/461.16 cGy) to 45.86%/32.54% (963.06/683.34 cGy) of prescription
dose, with a median of 32.86%/30.36% (690.06/637.56 cGy) and mean of 32.54%/28.22%
13

(683.34/592.62 cGy). On LINAC-BOOST plans, the femoral heads Dmax ranged from
26.22%/30.95% (550.62/649.95 cGy) to 37.29%/37.59% (783.09/789.39 cGy) of prescription
dose, with a median of 35.21%/35.69% (739.41/749.49 cGy) and mean of 32.54%/35.36%
(683.34/742.6 cGy). A Wilcoxon signed-rank test indicated that there was no significant
difference for the left femoral head, but that the LINAC-BOOST right femoral head was
significantly higher than the CK-BOOST femoral head, Z = 5.5/22.5, p = 0.57/0.004.
The femoral heads mean dose was also evaluated on both plans. The CK-BOOST plans
showed a median left/right femoral head dose of 226.31 cGy/148.78 cGy, with a range of 115.75
cGy/115.63 cGy to 442.53 cGy/265.85 cGy, with a mean of 245.15 cGy/169.19 cGy. On
LINAC-BOOST plans, the femoral heads mean dose ranged from 248.9 cGy/229.2 cGy to 500.3
cGy/461.3 cGy, with a median of 314.8 cGy/303.2 cGy and a mean of 329.02 cGy/316.6 cGy.
After performing a Wilcoxon signed-rank test, it is statistically significant that the LINACBOOST femoral heads mean was higher than the CK-BOOST femoral heads mean, Z =
22.5/22.5, p = 0.004/0.004. The left/right femoral head V8 constraint only applied to 3 of the
CK-BOOST plans (within tolerance), so they were not included in the statistics.
Sigmoid
On CK-BOOST plans, the sigmoid Dmax dose ranged from 0% (0 cGy) to 45.43%
(954.03 cGy) of prescription dose, with a median of 24.62% (517.02 cGy) and mean of 23.9%
(501.9 cGy). On LINAC-BOOST plans, the sigmoid Dmax ranged from 0% (0 cGy) to 27.49%
(577.29 cGy) of prescription dose, with a median of 7.41% (155.61 cGy) and mean of 9.37%
(196.77 cGy). A Wilcoxon ranked-sign test indicated that the CK-BOOST sigmoid Dmax is
significantly higher than the LINAC-BOOST sigmoid Dmax , Z = -17, p = 0.016.

14

The sigmoid mean dose was also evaluated on both plans. The CK-BOOST plans showed
a median sigmoid dose of 81.57 cGy, with a range of 0 cGy to 318.21 cGy, with a mean of
141.55 cGy. On LINAC-BOOST plans, the sigmoid mean dose ranged from 0 cGy to 121.7 cGy,
with a median of 80.1 cGy and a mean of 66.81 cGy. After performing a Wilcoxon signed-rank
test, it is statistically significant that the CK-BOOST sigmoid mean is higher than the LINACBOOST sigmoid mean, Z = -17, p = 0.016. The Sigmoid V15 [cc] constraint did not apply to any
plans as they received less than 15 Gy dose.
Bowel
On CK-BOOST plans, the bowel Dmax dose ranged from 0% (0 cGy) to 96.41%
(2024.61 cGy) of prescription dose, with a median of 0% (0 cGy) and mean of 16.03% (336.63
cGy). On LINAC-BOOST plans, the bowel Dmax ranged from 0% (0 cGy) to 64.83% (1361.43
cGy) of prescription dose, with a median of 0% (0 cGy) and mean of 9.59% (201.39 cGy). A
Wilcoxon signed-rank test indicated that there were no significant differences in bowel Dmax, Z
= -3, p = 0.25.
The bowel mean dose was also evaluated on both plans. The CK-BOOST plans showed a
median bowel dose of 0 cGy, with a range of 0 cGy to 285.7 cGy, with a mean of 68.74 cGy. On
LINAC-BOOST plans, the bowel mean dose ranged from 0 cGy to 111.3 cGy, with a median of
0 cGy and a mean of 31.92 cGy. After performing a Wilcoxon ranked-sign test, there was no
significant difference in bowel mean, Z = -3, p = 0.25. The bowel V15 [cc] constraint only
applied to 1 of the CK-BOOST plans (within tolerance), so they were not included in the
statistics.
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External genitalia
On CK-BOOST plans, the external genitalia Dmax dose ranged from 2.47% (51.87 cGy)
to 12.57% (263.97 cGy) of prescription dose, with a median of 4.23% (88.83 cGy) and mean of
5.36% (112.56 cGy). On LINAC-BOOST plans, the external genitalia Dmax ranged from 0.83%
(17.43 cGy) to 12.79% (268.59 cGy) of prescription dose, with a median of 2.64% (5.54 cGy)
and mean of 4.31% (90.51 cGy). A Wilcoxon signed-rank test indicated that there was no
significant difference in external genitalia Dmax, Z = -9.5, p = 0.30.
The external genitalia mean dose was also evaluated on both plans. The CK-BOOST
plans showed a median external genitalia dose of 36 cGy, with a range of 21.79 cGy to 50 cGy,
with a mean of 34.96 cGy. On LINAC-BOOST plans, the external genitalia mean dose ranged
from 8.2 cGy to 41 cGy, with a median of 19.8 cGy and a mean of 21.12 cGy. After performing
a Wilcoxon signed-rank test, it is statistically significant that the CK-BOOST external genitalia
mean is higher than the LINAC-BOOST external genitalia mean, Z = -21.5, p = 0.008.

Discussion
PTV coverage
The prescription dose to >95% of the PTV recommendation was not achieved on three
out of the nine CK-BOOST plans, but the mean of all plans did remain at 95.49% 12. These same
recommendations were met by all the LINAC-BOOST plans with the mean of 96.14%
prescription dose. The CK-BOOST were superior in a higher PTV Dmin, with an average mean
of about 8% higher prescription dose going to the treated volume. The CK-BOOST plans in this
study shared a similar results as a single fraction SBRT for spinal metastasis study completed in
2010 with a more optimal Dmin than its LINAC based counterpart 9.
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Another factor that made the CK-BOOST more ablative was the higher average Dmax,
which was about a 4% higher mean than the LINAC-BOOST. A comparison boost plan as well
as a DVH can be seen in figure 8 to show the quantitative and visual differences when factoring
the equivalent biological dose. The composite of the same patient can be viewed in figure 9 to
give a better sense of the overall treatment course.
OAR sparing
Overall, both the LINAC-BOOST and CK-BOOST were able to meet most constraints
that were set by the Hirsch, A. observational study. Both plans did struggle with the rectum
V19.5 [cc] constraint on the patient that had a double metal hip prosthesis, going slightly over
the 2cc minor variation limit. Both plans also showed a minor variation with the bladder V19.5
[cc] constraint on the same two patients, which can likely be attributed to patient anatomy as
both modalities had similar results. There was also a minor variation of 1.7 cc for bowel V15
[cc] in a single CK-BOOST plan. These slight variations could have been due to a multitude of
factors including but not limited to planning time allotted, constraint weighting, elimination of
beams to shorten treatment time (CK plans), etc.
The LINAC-BOOST plans had better overall OAR sparing for every organ which could
be seen in the significant findings of the results after running a Wilcoxen-signed rank test. The
LINAC plans had significantly lower rectum mean, V19.5 [cc], 18.9 (%), 16.8 (%), bladder
mean, V19.5 [cc], V18.9 (%), penile bulb mean, Dmax, and sigmoid Dmax. The CK-BOOST,
however, showed significantly lower bladder Dmax, right femoral head Dmax, and Femoral head
means. A 2019 study on SBRT used to treat low-risk prostate adenocarcinoma with a variety of
treatment modalities similarly revealed statistically better rectum sparing by LINAC-based
IMRT techniques6.
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One patient had a metal hip prosthesis which led to the addition of 4 additional VMAT
arcs for the LINAC-BOOST plans. The Dmax of the rectum and bladder were both over 10%
lower for the CK-BOOST plans on the same patient. This is largely due to the use of noncoplanar beams of CK which allowed complete avoidance of the prosthesis. A comparison boost
plan as well as a DVH can be seen in figure 10 to show the quantitative and visual differences
when factoring the equivalent biological dose.
Patient perspective
The LINAC-BOOST and CK-BOOST offer the same hypofractionated schedule as
conventional prostate boost treatments, which can range from 27-41 Gy dependent on pelvic
nodal involvement and whether the treatment is definitive, adjuvant, or salvage 7.
Hypofractionated options allow the patient to receive treatment in one week compared to 2-3
weeks for conventional boost. This allows the patient to get back to their pre-treatment schedule
sooner and start an early healing process early. While both SBRT boost treatments offer a similar
treatment course, the mean LINAC-BOOST delivery time was 4.79 minutes while the CKBOOST plans were 48 minutes which can be seen in table 2. The treatment time presented does
not factor in the set-up time, imaging, or couch shifts that may be required.
Limitations and future research
One of the main shortcomings of this study is that the boost plans were planned by two
different individuals, the CK-BOOST planner having 4+ years of experience as a dosimetrist
while the LINAC-BOOST planner had less than one year. Another limitation was that the
LINAC-BOOST plans were planned on the machine that the patient received their primary
treatment on to give the sense of how the treatment would continue. There is only one of the
machines that SBRT cases are planned on at this southwestern center due to table stability and
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micro-MLC’s and that is the Elekta Infiniti. Another major factor not considered for this study is
if the LINAC-BOOST plans are deliverable, as the plans were evaluated visually and
dosimetrically in the TPS and patient specific quality assurance plans were not run for these
plans.
For future studies, the same dosimetrist could be used for all plans to achieve a true
comparison based on the experience level of the planner. In addition, the patients could be
planned for a single linear accelerator regardless of where they received primary treatment. The
normalization and optimization goals can also skew OAR sparing and PTV coverage. As a
solution for future studies, the range of normalization could be kept very small (within 5-10%) to
maintain a similar global maximum range and create comparative plans. One addition to this
study that would help verify accurate machine delivery of plans compared to the TPS is to run
patient-specific QA on a mapcheck. LINAC-BOOST patients could also be re-simulated with the
required body immobilization to give a better delineation of PTV and OAR during treatment 4.

Conclusion
The study showed that both boost plans provided adequate PTV coverage and were able
to meet most constraints equally. The CK-BOOST plans did however have a more optimal Dmin
overall. Another positive aspect of CK was maintaining a lower OAR hotspot for cases with
metal implants. On the other hand, LINAC-BOOST plans average beam on time was about a
tenth of the CK plans. Men who are treated with either LINAC or CK SBRT for prostate boost
are going to receive similar overall treatments with a higher biologically effective dose with CK.
Further studies are needed to assess a more accurate quantitative comparison of linear accelerator
versus Cyberknife for prostate SBRT boost treatments.
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Table 1. PTV Coverage Table
Analysis Variable: VAR3 PTV (%%Rx)
Prostate
N
Boost Plan Obs N Mean Median Std Dev Minimum Maximum
CK SBRT
9 9 95.49 95.90
1.59
93.38
97.99
LINAC SBRT
9 9 96.14 95.73
1.13
95.13
98.49

Figure 1. Rectum 19.5 Gy [cc] Box Plot

Figure 2. Rectum 18.9 Gy (%) Box Plot

23

Figure 3. Rectum 16.8 Gy (%) Box Plot

Figure 4. Rectum 10.5 Gy (%) Box Plot

Figure 5. Bladder 19.5 Gy [cc] Box Plot

24

Figure 6. Bladder 18.9 Gy (%) Box Plot

Figure 7. Bladder 10.5 Gy (%) Box Plot
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Figure 8. Prostate Boost Plan Comparison (Patient_A)

Figure 9. Prostate Composite Plan Comparison (Patient_A)
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Figure 10. Prosthetic Hip Prostate Boost Comparison (Patient_C)

Table 2. Treatment Delivery Time Box Plot
Analysis Variable : Treatment_Time__Min_ Treatment Time (Min)
Prostate
N
Boost Plan Obs
N Mean Median Std Dev Minimum Maximum
CK SBRT
9
9 48.00 49.00
5.41
38.00
56.00
LINAC SBRT
9
9 4.79
4.50
1.01
4.15
7.42
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